Fomepizole oral - Horizon Pharma

Drug Profile

Fomepizole oral - Horizon Pharma

Alternative Names: 4-Methylpyrazole; 4-MP - Horizon Pharma; Convivia

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator Convivia
  • Developer Horizon Pharma
  • Class Antidotes; Pyrazoles; Small molecules
  • Mechanism of Action Alcohol dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Metabolic disorders

Most Recent Events

  • 01 Sep 2015 Clinical development is ongoing in the USA
  • 12 Aug 2014 Fomepizole oral is still in phase II development for Metabolic disorders
  • 07 Jul 2014 Fomepizole oral - Raptor Therapeutics is available for licensing in Asia (excluding Taiwan) as of 07 Jul 2014. http://www.raptorpharma.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top